secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001437749-26-007828
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports FY2025 net loss $26.2M; cash $5.2M; FDA type C meeting planned
----------------------------------------------------------------------------

- Net loss of $26.2M ($2.65 per share) vs $39.4M ($5.67) in 2024.
- R&D expenses $14.0M, down from $20.1M; G&A $9.2M, down from $13.3M.
- Cash and equivalents $5.2M at Dec 31, 2025; expected runway to Q3 2026 after Jan 2026 offering.
- Oversubscribed $28M registered direct offering; initial tranche $6M priced above market.
- Type C FDA meeting before end of Mar 2026; NDA filing for CNM-Au8 in ALS by June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/0001437749-26-007828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/clnn20251022_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer